Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT05181826
Official study title

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Study summary

To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedMulti-analyte Blood Test

The study team can explain what participation involves.

Who it may be forCancer · Liver Cirrhosis

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 10, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Helio Genomics

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Helio Genomics
Interventions being studied
Diagnostic Test: Multi-analyte Blood Test
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

2.1.1 Age 18 years or older. 2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. .

Reasons someone may not be able to joinExclusion criteria

2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded. 2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Torrance Memorial Physician Network - Cancer CareRedondo Beach, California
  • Allina Health, Virginia Piper Cancer InstituteCoon Rapids, Minnesota
  • Virginia Piper Cancer Institute Mercy Hospital-Unity CampusFridley, Minnesota
  • VPCI Oncology ResearchMinneapolis, Minnesota
  • Methodist LeBonheur HealthcareMemphis, Tennessee
  • Liver Center of TexasDallas, Texas
  • Methodist HospitalRichardson, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 10, 2026. Always confirm current availability with the study team.

View original record ↗